Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIMIDEX vs. NOLVADEX in post-menopausal breast cancer
NCT00232661Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2000
- Primary completion
- Jan 2003
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of anastrozole in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Objective tumour response at 3 months. Started Aug 2000; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00232661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232661.